Clinuvel Pharmaceuticals Limited
CUV.AXClinuvel Pharmaceuticals Limited in brief
Clinuvel Pharmaceuticals Limited is a listed company in the Biotechnology industry, based in Australia. It was founded in 2001. Its last known market value was $538 M (January 2024); there is no current figure. In the year to June 2026 it had sales of $64 M and a net profit of $23 M, about 36 cents of profit for every dollar of sales. Its largest product and service lines by sales in 2026 were Commercial Sales of Goods (90%) and Sales Under Special Access Reimbursement Programs (10%). By market, the largest shares of its 2026 sales came from Ireland (56%) and USA (43%). Its shares trade under the symbol CUV.AX (ASX).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals is a Biopharmaceutical company. The company focused on developing and commercializing treatments for patients with genetic, metabolic and life threatening disorders as well as healthcare solutions for the general population. The headquarters is in Australia.
Clinuvel Pharmaceuticals Limited timeline
- 2001
- 🏁· approximateFounded
- 🔔Initial public offering on Australian Securities Exchange as CUV
- 2018
- •Legal Entity Identifier issuedLEI 5299004VJH3VCYLK6519 registered.
Events of Clinuvel Pharmaceuticals Limited from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Australia: #89 (Jan 2020) · #196 (Jan 2021) · #216 (Jan 2022) · #207 (Dec 2022) · #232 (Jul 2023) · #246 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 36.0%
- Operating margin
- 43.4%
- Return on equity
- 12.3%
- Liabilities / assets
- 7.5%
- Revenue growth
- +5.2%
- R&D / revenue
- 19.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $64M | +5.2% | $28M | $23M | 36.0% |
| Jun 2025 | $61M | +5.5% | $27M | $23M | 37.8% |
| Jun 2024 | $58M | — | $29M | $23M | 40.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $13M | $1M | $12M | $0.46 | — |
| Jun 2025 | $27M | $0M | $27M | $0.46 | — |
| Jun 2024 | $24M | $4M | $20M | $0.46 | — |
SEC filings
- Oct 30, 202620-FAnnual report (foreign issuer) · period to Jun 2026
- Oct 30, 20266-KReport of foreign issuer
- Oct 15, 20266-KReport of foreign issuer
- Oct 7, 20266-KReport of foreign issuer
- Oct 2, 20266-KReport of foreign issuer
- Oct 1, 20266-KReport of foreign issuer
- Sep 9, 20266-KReport of foreign issuer
- Aug 27, 20266-KReport of foreign issuer
- Aug 20, 20266-KReport of foreign issuer
- Aug 12, 20266-KReport of foreign issuer
- Jul 30, 20266-KReport of foreign issuer
- Jul 28, 20266-KReport of foreign issuer
Official filings of Clinuvel Pharmaceuticals Limited with the US Securities and Exchange Commission.
Annual results
- Revenue
- $64 M
- Operating income
- $28 M
- Net income
- $23 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $204 M
- Total liabilities
- $15 M
- Total equity
- $189 M
As of June-2026
Mutual funds holding Clinuvel Pharmaceuticals Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc. | 567,868 | $4 M | — | <0.01% | −3.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc. | 415,309 | $3 M | — | <0.01% | +7.9% | Jun 30, 2026 |
| 🇺🇸 The Asia Pacific Small Company SeriesDimensional Fund Advisors LP | 243,732 | $2 M | — | 0.09% | +29% | Jul 31, 2026 |
| 🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc. | 178,331 | $1 M | — | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP | 97,682 | $1 M | — | <0.01% | +113% | Jul 31, 2026 |
| 🇺🇸 Schwab International Small-Cap Equity ETFCharles Schwab Investment Management, Inc. | 87,840 | $1 M | — | 0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 54,142 | $0 M | — | <0.01% | +152% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 53,540 | $0 M | — | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Vanguard Pacific Stock Index FundThe Vanguard Group, Inc. | 52,162 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 47,436 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 33,382 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 23,430 | $0 M | — | 0.02% | +1.0% | Jun 30, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 20,079 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc. | 17,121 | $0 M | — | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors | 18,682 | $0 M | — | 0.02% | +2.1% | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 10,919 | $0 M | — | <0.01% | −39% | Jul 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 8,461 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP | 8,605 | $0 M | — | <0.01% | +171% | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 6,680 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 6,591 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 5,455 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust | 5,143 | $0 M | — | 0.01% | +18% | May 31, 2026 |
| 🇺🇸 Dimensional International Small Cap Value ETFDimensional Fund Advisors LP | 4,630 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 4,611 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 3,103 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 2,335 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 1,998 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC | 760 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP | 514 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: Clinuvel Pharmaceuticals Limited#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 500 shares at $5.07
- : 54 shares at $5.00
- : 43 shares at $5.49
- : 1,810 shares at $5.69
- : 1,513 shares at $5.56
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Clinuvel Pharmaceuticals Limited scorecard#
Passes 9 of the 11 checks that could be worked out: strongest in shareholder returns (4 of 4), weakest in profitability (2 of 3). Fiscal year 2026.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- ✓Revenue grew in the newest year5.2%Revenue up 5.2% in fiscal 2026.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year0.46 vs 0.46Diluted EPS 0.46 in fiscal 2026 against 0.46 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 3
- ✓Profitable in the newest year$23 MNet income $23 M in fiscal 2026.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median43.4%43.4% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%13.4%13.4% in fiscal 2026.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 2
- ✓Short-term assets cover short-term liabilities14.7×Current ratio 14.72 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2026.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns4 of 4
- ✓Pays a dividendYesPaid dividends in fiscal 2026.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- ✓Dividends under 75% of net income7.2%Dividends were 7.2% of net income in fiscal 2026.
- ✓Share count up no more than 2% in a year0.7%Diluted shares up 0.7% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- ✓Free cash flow covers dividends and buybacks$12 MFree cash flow $12 M against $2 M paid out in fiscal 2026.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2026#
Worked out from Clinuvel Pharmaceuticals Limited's statements, beside the median of Biotechnology.
| Ratio | Trend | 2026 | Median of peers |
|---|---|---|---|
| Operating margin | 43.4% | -60.5% | |
| Net margin | 36.0% | -68.9% | |
| Return on equity | 13.4% | -61.0% | |
| Revenue growth | 5.2% | 15.8% | |
| Free cash flow margin | 18.4% | -61.5% |
4of 8on the Piotroski tests of financial strength
Clinuvel Pharmaceuticals Limited: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 64+5.2%100% | 61+5.5%100% | 58—100% | |
| Cost of revenue | 11−4.6%17.1% | 12+7.2%18.8% | 11—18.5% | |
| Gross profit | 53+7.5%82.9% | 50+5.2%81.2% | 47—81.5% | |
| Research and development | 12−7.5%19.0% | 13+32.2%21.6% | 10.0—17.3% | |
| General and administrative | 7.4+10.6%11.5% | 6.7−2.0%10.9% | 6.8—11.8% | |
| Operating expenses | 25+10.1%39.5% | 23+23.8%37.8% | 19—32.2% | |
| Operating income | 28+5.3%43.4% | 27−7.0%43.4% | 29—49.3% | |
| Interest and finance income | 7.1+15.8%11.0% | 6.1+27.2%10.0% | 4.8—8.3% | |
| Other non-operating income (expense) | 0.5—0.7% | −0.1−138%−0.2% | 0.4—0.6% | |
| Income before tax | 33−1.1%50.9% | 33−0.4%54.1% | 33—57.4% | |
| Income tax | 9.5−4.3%14.8% | 10.0+1.0%16.3% | 9.9—17.1% | |
| Net income attributable to shareholders | 23+0.2%36.0% | 23−1.0%37.8% | 23—40.3% | |
| Earnings per share, basic | 0.460.0%— | 0.46−2.1%— | 0.47—— | |
| Earnings per share, diluted | 0.460.0%— | 0.460.0%— | 0.46—— | |
| Shares, weighted average (basic) | 50−0.1%— | 50+0.5%— | 50—— | |
| Shares, weighted average (diluted) | 51+0.7%— | 50−1.3%— | 51—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 14−23.0%6.8% | 18—10.2% | — | |
| Short-term investments | 160+25.6%78.5% | 127—72.1% | — | |
| Receivables | 16−8.8%7.9% | 18+1.4%10.0% | 18—— | |
| Inventory | 4.8−17.1%2.3% | 5.7—3.2% | — | |
| Other current assets | 1.6−7.2%0.8% | 1.7—1.0% | — | |
| Current assets | 197+15.1%96.3% | 171—96.6% | — | |
| Property, plant and equipment | 5.0+12.0%2.5% | 4.5—2.6% | — | |
| Right-of-use (leased) assets | 1.4+333%0.7% | 0.3—0.2% | — | |
| Other intangible assets | 0.1+6.3%0.1% | 0.1—0.1% | — | |
| Total assets | 204+15.4%100% | 177—100% | — | |
| Accounts payable | 1.0−37.8%0.5% | 1.7—0.9% | — | |
| Customer deposits | 160+25.6%78.5% | 127—72.1% | — | |
| Current liabilities | 13−24.3%6.5% | 18—10.0% | — | |
| Lease liabilities (non-current) | 1.1+1929%0.5% | 0.1—0.0% | — | |
| Total liabilities | 15−23.2%7.5% | 20—11.3% | — | |
| Retained earnings | 69+45.7%33.6% | 47—26.6% | — | |
| Shareholders' equity | 189+20.3%92.5% | 157+16.1%88.7% | 135—— | |
| Total liabilities and equity | 204+15.4%100% | 177—100% | — | |
| Shares outstanding | 50+0.6%— | 50—— | — | |
| Cash-flow statement | ||||
| Share-based compensation | 1.6+22.9%2.5% | 1.3−68.2%2.1% | 4.1—7.0% | |
| Cash from operating activities | 13−52.7%20.1% | 27+14.9%44.7% | 24—41.0% | |
| Capital expenditure | −1.1—−1.6% | −0.2—−0.3% | −3.7—−6.3% | |
| Cash from investing activities | −26—−39.9% | −31—−50.1% | −19—−33.2% | |
| Shares bought back | — | −0.2—−0.3% | −0.5—−0.9% | |
| Dividends paid | −1.7—−2.6% | −1.7—−2.8% | −1.6—−2.7% | |
| Cash from financing activities | −1.7—−2.6% | −1.9—−3.1% | −2.1—−3.6% | |
| Change in cash | −4.1—−6.4% | −5.2−332%−8.6% | 2.3—3.9% | |
| Report | 20-F | 20-F | 20-F | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Clinuvel Pharmaceuticals Limited sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Commercial Sales of Goods$58 M90%+4.1%
- Sales Under Special Access Reimbursement Programs$6 M10%+16%
Countries and regions
- 🇮🇪 Ireland$36 M56%+21%
- 🇺🇸 USA$28 M43%-9.9%
- Rest of World$1 M0.9%-5.2%
Source: SEC annual report (XBRL data) · as of Jun 30, 2026
Where Clinuvel Pharmaceuticals Limited operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇦🇺 Australia | Headquarters2 offices | — |
| 🇮🇪 Ireland | $36 M56% | |
| 🇺🇸 USA | $28 M43% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
How Clinuvel Pharmaceuticals Limited compares in Biotechnology
- Revenue$64 M · higher than 62% of 647
- Net margin36.0% · higher than 94% of 408
- Revenue growth5.2% · higher than 49% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Clinuvel Pharmaceuticals Limited🇦🇺 | $538 M | — | 36.0% | +5.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Clinuvel Pharmaceuticals Limited? Verify and update this profile — free
Show Clinuvel Pharmaceuticals Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.